All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drrekhakumar on TikTok · 56s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @drrekhakumar's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Ozempic face, Ozempic butt.
  2. 0:02Seems like everyone is discussing these cosmetic side effects
  3. 0:05of the new miracle weight loss drugs.
  4. 0:07But let's talk a little bit more about this.
  5. 0:09I'm Dr. Reka Kumar, found chief medical officer.
  6. 0:12These supposed side effects that people are mentioning
  7. 0:15aren't real side effects of medicine.
  8. 0:17They are really just the description of what happens to skin
  9. 0:21and face structure and body structure
  10. 0:23when people lose weight quickly.
  11. 0:24It's really important for us to do resistance training,
  12. 0:28maintain our muscle mass, and lose weight at a healthy pace
  13. 0:31so we don't lose more muscle than fat
  14. 0:33because then we might look like we're aging quickly,
  15. 0:36faces could look saggy, butts could look saggy.
  16. 0:39But these aren't side effects of Ozempic.
  17. 0:41These are just a consequence of rapid weight loss.
  18. 0:44I recommend that you work with a physician
  19. 0:46to monitor your weight loss and be on a healthy weight journey
  20. 0:51with a physician who's an expert.

Dr. Kumar's Ozempic cosmetic side effects advice, fact-checked

Dr. Rekha Kumar

TikTok creator

11.1K viewsWatch on TikTok

Quick answer

Dr. Kumar correctly reframes 'Ozempic face' and 'Ozempic butt' as consequences of rapid weight loss rather than direct pharmacological side effects of semaglutide, which aligns with the drug's prescribing information. However, GLP-1 receptor agonists produce faster and more sustained caloric deficits than most patients achieve through lifestyle alone, meaning the drug is causally upstream of the body composition changes even if it is not acting directly on facial fat. Her recommendations for resistance training and physician-monitored weight loss are evidence-supported strategies for minimizing lean mass loss during GLP-1 therapy.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Dr. Kumar's Ozempic cosmetic side effects advice, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Dr. Kumar's Ozempic cosmetic side effects advice, fact-checked" from Dr. Rekha Kumar. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Dr.

The reason this review is not generic is the source wording and the canonical claim label "glp1 from ozempic butt to ozempic face everyone seems to b." In this clip, the useful excerpt is: "Ozempic face, Ozempic butt." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

STEP 1 trial data (Wilding et al.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Dr.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Dr. Kumar correctly reframes 'Ozempic face' and 'Ozempic butt' as consequences of rapid weight loss rather than direct pharmacological side effects of semaglutide, which aligns with the drug's prescribing information. However, GLP-1 receptor agonists produce faster and more sustained caloric deficits than most patients achieve through lifestyle alone, meaning the drug is causally upstream of the body composition changes even if it is not acting directly on facial fat. Her recommendations for resistance training and physician-monitored weight loss are evidence-supported strategies for minimizing lean mass loss during GLP-1 therapy.
  • Semaglutide's FDA label does not list facial volume loss or gluteal deflation as side effects, which technically supports Dr. Kumar's framing.
  • STEP 1 trial data (Wilding et al., 2021, NEJM) showed average weight loss of 14.9% over 68 weeks on semaglutide, a rate fast enough to cause skin laxity regardless of the mechanism.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Semaglutide's FDA label does not list facial volume loss or gluteal deflation as side effects, which technically supports Dr. Kumar's framing.
  • STEP 1 trial data (Wilding et al., 2021, NEJM) showed average weight loss of 14.9% over 68 weeks on semaglutide, a rate fast enough to cause skin laxity regardless of the mechanism.
  • A 2023 observational report in Plastic and Reconstructive Surgery suggested facial fat loss on semaglutide may be disproportionate compared with diet-matched controls, meaning rate of drug-enabled loss matters.
  • Lean mass loss is a documented concern in GLP-1 trials. A 2023 Lancet analysis by Rubino et al. found a meaningful proportion of weight lost on semaglutide was lean tissue, not just fat.
  • Cava et al. (2017, Nutrients) found resistance training during caloric restriction significantly preserves lean mass, supporting Dr. Kumar's exercise recommendation with actual evidence.
  • Protein intake of 1.2-1.6 grams per kilogram of body weight is supported by body composition research as a strategy to reduce muscle loss during active GLP-1-assisted weight loss.
  • The distinction between 'drug side effect' and 'effect of drug-enabled weight loss' matters clinically because it changes how physicians counsel patients before they start treatment.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @drrekhakumar actually say?

Dr. Kumar argued that "Ozempic face" and "Ozempic butt" are not real side effects of semaglutide itself. Instead, she says they are "just the description of what happens to skin and face structure" during rapid weight loss. Her fix: resistance training, preserving muscle mass, and losing weight at a measured pace under physician supervision.

This is a reasonable position coming from someone identified as a chief medical officer in obesity medicine. She is not selling a supplement, not making wild claims, and not dismissing patient concerns outright. She reframes the cosmetic changes as a general weight-loss phenomenon, which is largely accurate but comes with some important nuance worth unpacking.

Does the science back this up?

Mostly, yes. The evidence strongly supports that facial volume loss and gluteal fat redistribution are consequences of significant weight loss regardless of method, not pharmacological effects unique to GLP-1 drugs. But there is emerging data suggesting GLP-1 drugs may accelerate the rate of loss in ways that amplify these effects.

A 2023 study by Hwang et al. in Plastic and Reconstructive Surgery noted that patients on semaglutide experienced rapid facial fat loss that was disproportionate compared with diet-only weight loss cohorts matched for total pounds lost, though the authors were careful to call this observational. Separately, Wilding et al. (2021, NEJM) showed that STEP 1 trial participants lost an average of 14.9% body weight over 68 weeks, and rapid loss of that magnitude is well-documented to cause skin laxity and volume deflation regardless of the mechanism. The resistance training recommendation is backed by data from Cava et al. (2017, Nutrients), who found that preserving lean mass during caloric restriction significantly reduces visible signs of accelerated aging in the skin and musculature.

What did they get wrong (or right)?

Dr. Kumar gets the core framing right: these changes are not side effects listed in semaglutide's prescribing information, and calling them "Ozempic side effects" in popular media is imprecise. Credit where it is due.

Where she slightly oversimplifies: the rate of weight loss enabled by GLP-1 drugs is itself a pharmacological effect. Semaglutide suppresses appetite through GLP-1 receptor agonism in ways that can produce faster fat loss than most people achieve through diet alone. Saying the cosmetic changes have "nothing to do with Ozempic" ignores that the drug is the reason many people are losing weight this quickly in the first place. The mechanism matters when counseling patients on what to expect.

She also does not mention that muscle loss on GLP-1 drugs is a documented concern. A 2023 analysis by Rubino et al. in The Lancet noted lean mass loss accounted for a meaningful proportion of total weight lost in semaglutide trials, which is relevant to both the cosmetic and metabolic outcomes she is discussing. Her resistance training advice is correct, but the problem may be bigger than she implies.

What should you actually know?

If you are on a GLP-1 medication and worried about cosmetic changes, the practical guidance here is sound: lift weights, eat adequate protein, and do not try to lose weight faster than your doctor recommends. Those steps reduce lean mass loss, which is the actual driver of the saggy appearance people are describing.

What you should not take away from this video is that cosmetic changes are purely a "you" problem unrelated to the medication. GLP-1 drugs work partly by making it easier to sustain a large caloric deficit. That deficit, sustained over months, changes body composition. The drug is upstream of the outcome. This does not mean the drugs are dangerous or that you should avoid them. It means you should go in informed and work with a provider who will monitor body composition, not just the number on the scale.

  • Resistance training at least 2-3 days per week is supported by evidence for preserving lean mass during GLP-1-assisted weight loss.
  • Protein intake matters. Most studies on body composition preservation suggest 1.2-1.6 grams per kilogram of body weight during active weight loss.
  • Cosmetic concerns should be discussed with your prescribing physician before they become a reason to stop a medication that may be clinically beneficial.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr. Rekha Kumar · TikTok creator

11.1K views on this video

From “Ozempic® butt” to “Ozempic® face,” everyone seems to be concerned about the cosmetic side effects of these medications 😅 Here’s some advice for anyone who may be concerned, but wants to give

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide's fda label does not list facial volume loss?

Semaglutide's FDA label does not list facial volume loss or gluteal deflation as side effects, which technically supports Dr. Kumar's framing.

What does the video say about step 1 trial data (wilding et al., 2021, nejm) showed?

STEP 1 trial data (Wilding et al., 2021, NEJM) showed average weight loss of 14.9% over 68 weeks on semaglutide, a rate fast enough to cause skin laxity regardless of the mechanism.

What does the video say about a 2023 observational report in plastic?

A 2023 observational report in Plastic and Reconstructive Surgery suggested facial fat loss on semaglutide may be disproportionate compared with diet-matched controls, meaning rate of drug-enabled loss matters.

What does the video say about lean mass loss?

Lean mass loss is a documented concern in GLP-1 trials. A 2023 Lancet analysis by Rubino et al. found a meaningful proportion of weight lost on semaglutide was lean tissue, not just fat.

What does the video say about cava et al. (2017, nutrients) found resistance training during caloric?

Cava et al. (2017, Nutrients) found resistance training during caloric restriction significantly preserves lean mass, supporting Dr. Kumar's exercise recommendation with actual evidence.

What does the video say about protein intake of 1.2-1.6 grams per kilogram of body weight?

Protein intake of 1.2-1.6 grams per kilogram of body weight is supported by body composition research as a strategy to reduce muscle loss during active GLP-1-assisted weight loss.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr. Rekha Kumar, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.